Glaucoma Market Forecast to 2030: Industry Trends and Insights

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Anticipated Rise In Market Value Of The Glaucoma Market During The Forecast Period?

The glaucoma market has experienced robust expansion in recent years. It is projected to grow from $8.2 billion in 2025 to $8.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. This historical growth can be primarily ascribed to factors such as an aging population, a higher prevalence of eye diseases, advancements in ophthalmic diagnostics, the early adoption of drug therapy, and the increasing number of eye clinics.

The glaucoma market is projected to experience substantial expansion over the coming years, reaching a valuation of $10.62 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is primarily driven by advancements in imaging technology, the proliferation of surgical innovations, widespread digital eye health monitoring, various early detection programs, and increasing investments in ophthalmology. Key developments expected within this period encompass a greater acceptance of early diagnostic screening, a rise in the application of combination drug therapies, the progression of minimally invasive glaucoma surgery, the broadening of home-based eye monitoring solutions, and enhanced patient awareness campaigns.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

What Primary Drivers Are Shaping The Glaucoma Market?

The glaucoma market is anticipated to expand due to the increasing occurrence of chronic eye conditions. These are enduring ocular ailments, frequently leading to ongoing vision problems or discomfort and necessitating continuous care or therapy. Their increase can be attributed to an aging populace, greater screen exposure, lifestyle choices, and a higher incidence of diseases such as diabetes and hypertension. Managing chronic eye conditions necessitates glaucoma treatment to reduce intraocular pressure, avert additional optic nerve damage, and safeguard vision, given that untreated glaucoma may result in permanent blindness. As an illustration, data from December 2024 by the National Health Service (NHS), the UK’s publicly funded healthcare system, indicates that more than 2 million individuals in the UK are experiencing sight loss in 2024. Moreover, this figure is predicted to rise by 27%, reaching around 2.8 million by 2035. Consequently, the growing prevalence of chronic eye conditions is fueling the glaucoma market.

How Is The Glaucoma Market Segmented Across Different Segment Categories?

The glaucoma market covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types

2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy

3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes

4) By Administration: Oral, Injections, Intravitreal, Other Administrations

5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

What Trends Are Affecting The Growth Of The Glaucoma Market?

Key companies in the glaucoma market are concentrating on developing innovative treatments, such as Rho-kinase (ROCK) inhibitors, which offer a dual mechanism of action. These therapies effectively reduce intraocular pressure by simultaneously enhancing the outflow of aqueous humor and relaxing trabecular meshwork cells, making them valuable in glaucoma management. Rho-kinase (ROCK) inhibitors constitute a drug class that targets and impedes the function of Rho-kinase enzymes, which are responsible for regulating cell contraction and contribute to glaucoma treatment by lowering intraocular pressure. For instance, in July 2023, Santen Pharmaceutical Co. Ltd., an eye care products company based in Japan, introduced Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) comprising latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, designed to efficiently decrease intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. It is indicated for adult patients experiencing primary open-angle glaucoma or ocular hypertension who have not achieved sufficient IOP reduction with monotherapy using either a prostaglandin or netarsudil. The debut of Roclanda in Europe marks the arrival of the first new class of glaucoma medication in 25 years, representing a significant advancement in treatment. By combining netarsudil and latanoprost, Roclanda functions synergistically to improve outflow through both trabecular (conventional) and uveoscleral (unconventional) pathways, providing a holistic approach to managing elevated IOP.

Which Organizations Play A Role In The Glaucoma Market Landscape?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Nidek Co. Ltd., Haag-Streit AG

Get The Full Glaucoma Market Report:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

Which Region Represents The Largest Share Of The Glaucoma Market?

North America was the largest region in the glaucoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Glaucoma Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/glaucoma-global-market-report

Browse Through More Reports Similar to the Global Glaucoma Market 2026, By The Business Research Company

Optic Atrophy Management Market Report 2026

https://www.thebusinessresearchcompany.com/report/optic-atrophy-management-global-market-report

Minimally Invasive Glaucoma Surgery Migs Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/minimally-invasive-glaucoma-surgery-migs-devices-global-market-report

Eye Melanoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795